Evidence map›Paper›PMID 31870442›Full record

ArticleBMC public health2019

Characteristics and health burden of the undiagnosed population at risk of chronic obstructive pulmonary disease in China.

Marco Koch, Thomas Butt, Wudong Guo, Xue Li, Yirong Chen, Diana Tan, Gordon G Liu

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. The Humanistic and Economic Burden of COPD Patients in Urban China: A Propensity Score Matching Study.International journal of chronic obstructive pulmonary disease · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020
    Article
  17. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Marco KochIndependent Research Consultant, Cologne, Germany.
Thomas ButtUCL Institute of Ophthalmology, University College London, London, UK. thomas.butt@ucl.ac.uk.ORCID http://orcid.org/0000-0002-0387-4550
Wudong GuoChina National Health Development Research Center, National Health Commission, Beijing, China.
Xue LiChina National Health Development Research Center, National Health Commission, Beijing, China.
Yirong ChenKantar Health, Singapore, Singapore.
Diana TanKantar Health, Shanghai, China.
Gordon G LiuNational School of Development, Peking University, Beijing, China.
China National Health Development Research Center · CNPeking University · CNTH Köln - University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in China. However, identifying patients has proved challenging, resulting in widespread under-diagnosis of the condition. We examined the prevalence of COPD diagnosis and COPD risk among adults in urban mainland China, the factors associated with having a COPD diagnosis or COPD risk, and the healthcare resource use and health outcomes of these groups compared with controls.

methodsRespondents to the 2017 National Health and Wellness Survey in China (n = 19,994) were classified into three groups: 'COPD Diagnosed', 'COPD Risk (undiagnosed)', and Control (unaffected), based on their self-reported diagnosis and Lung Function Questionnaire (LFQ) score. The groups were characterised by sociodemographic, health-related quality of life (HRQoL), productivity impairment, and healthcare resource use. Pairwise comparisons (t tests and chi-squared tests) and multivariable regression analyses were used to investigate factors associated with being at risk of, or diagnosed with, COPD.

results3320 (16.6%) respondents had a suspected risk of COPD but did not report receiving a diagnosis. This was projected to 105.3 million people, or 16.9% of adult urban Chinese. Of these respondents with an identified risk, only 554 (16.7%) were aware of COPD by name. Relative to those without COPD, those with a risk of COPD (undiagnosed) had significantly greater healthcare resource use, lower productivity and lower HRQoL not only compared to those without COPD, but also compared to people with a COPD diagnosis. Factors associated with increased odds of being at risk of COPD were older age, smoking, alcohol consumption, overweight BMI, occasional exercise, higher comorbidities, asthma diagnosis, being female, lower education, not being employed, and living in a high pollution province (p < 0.05).

conclusionsThere is a substantial group of individuals, undiagnosed, but living with a risk of COPD, who have impaired HRQoL, lower productivity and elevated healthcare resource use patterns. Case-detection tools such as the LFQ may prove a quick and cost-effective approach for identifying these at-risk individuals for further definitive testing and appropriate treatment in China.

Indexed as

Cost of IllnessAdultAgedChinaEfficiencyFemaleHealth SurveysHumansMaleMiddle AgedPatient Acceptance of Health CarePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRisk FactorsYoung AdultCase detectionChinaChronic obstructive pulmonary diseaseHealth-related quality of lifeLung function questionnaireNational health and wellness surveyProductivityResource useScreening

Identifiers

PMID31870442
PMCPMC6929419
OpenAlexW2995122838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.